L’Oréal India wins CCI approval to acquire Innovist parent Onesto Labs
India’s competition regulator has cleared L’Oréal India’s acquisition of 100% of Onesto Labs, parent of digital-first personal-care brands Bare Anatomy and Chemist at Play. Innovist’s founders will continue to operate the business under L’Oréal’s Consumer Products Division; a closing timeline was not disclosed.
What happened
L'Oréal India · CCI approved L’Oréal India’s acquisition of 100% of Onesto Labs, the Innovist parent of Bare Anatomy and Chemist at Play. Innovist’s founders
Key facts
- 100% shareholding acquisition of Onesto Labs by L'Oréal India
- 26 brands in L'Oréal India's portfolio
- 2 manufacturing units
- Innovist founded in 2019
- Onesto Labs rebranded as Innovist in 2022
- L'Oréal has operated in India since 1994
Why this matters
The transaction shows global beauty incumbents using acquisitions of founder-led, digital-native brands to gain local consumer relevance, e-commerce capabilities, and faster exposure to India’s personal-care growth.
What to watch
- Transaction closing announcement and disclosed purchase consideration or valuation indicators.
- Changes in founders’ titles, reporting lines, equity incentives and senior Innovist employee retention.
- Offline distribution expansion, including placement at Nykaa, Reliance Retail, Shoppers Stop, pharmacies and general trade.
- SKU rationalization, reformulations, new clinical claims or price-pack changes after integration.
- Marketplace ranking, review volume, repeat-rate signals and promotional intensity for Bare Anatomy and Chemist at Play.
- L’Oréal India’s next earnings commentary on Consumer Products Division growth, acquisition integration and India investment.
- Competitive responses from Honasa, Nykaa brands, Unilever, P&G and other science-led Indian personal-care entrants.
- Keep Innovist founders in visible operating and brand-building roles to preserve digital-native credibility and retention.
- Expand Bare Anatomy and Chemist at Play selectively into L’Oréal’s offline distribution network, prioritizing high-velocity pharmacy, beauty-specialty and modern-trade doors.
- Use L’Oréal R&D, claims substantiation and packaging procurement to accelerate clinically positioned hair, scalp, deodorant and bodycare launches.
- Integrate marketplace data, loyalty, CRM and media-buying capabilities to reduce customer-acquisition costs and improve repeat purchase.
- Evaluate additional India D2C acquisitions or minority investments in adjacent high-growth segments such as dermocosmetics, fragrance, men’s grooming and hair/scalp treatment.
Also reported by
- Mint · Companies — Same time